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Background: One of the major functions of Nef is in the enhancement of the infectivity of the human and simian
immunodeficiency viruses (HIV and SIV, respectively). However, the detailed mechanism of the enhancement of viral
infectivity by Nef remains unclear. Additionally, studies of mechanisms by which Nef enhances the infectivity of SIV
are not as intensive as those of HIV-1.
Methods: We generated short-lived Nef constructed by fusing Nef to a proteasome-mediated protein degradation
sequence to characterize the Nef role in viral infectivity.
Results: The apparent expression level of the short-lived Nef was found to be extremely lower than that of the
wild-type Nef. Moreover, the expression level of the short-lived Nef increased with the treatment with a proteasome
inhibitor. The infectivity of HIV-1 with the short-lived Nef was significantly lower than that with the wild-type Nef.
On the other hand, the short-lived Nef enhanced the infectivity of SIVmac239, an ability observed to be interestingly
equivalent to that of the wild-type Nef. The short-lived Nef was not detected in SIVmac239, but the wild-type Nef
was, suggesting that the incorporation of Nef into SIVmac239 is not important for the enhancement of SIVmac239
infectivity.
Conclusions: Altogether, the findings suggest that the mechanisms of infectivity enhancement by Nef are different
between HIV-1 and SIVmac239. Lastly, we propose the following hypothesis: even when the expression level of a
protein is extremely low, the protein may still be sufficiently functional.
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The negative regulatory factor (Nef ), a 27–35-kDa non-
enzymatic protein, is an accessory protein of human and
simian immunodeficiency viruses (HIV and SIV, respect-
ively) that enhances viral replication; it is associated with
the pathogenesis induced by these viruses both in vivo
and in vitro [1-4]. Furthermore, Nef has many functional
motifs for contact to host proteins [5], through which it
can serve as a molecular adaptor, and exert multiple
functions, like the downregulation of CD4 and major
histocompatibility complex (MHC) class I [6]. N-Myris-
toylation occurs at the N-terminus of Nef [7], whose* Correspondence: tkmnnbtk@gpo.kumamoto-u.ac.jp
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unless otherwise stated.posttranslational modification is essential for its multiple
functions [6].
One of the major functions of Nef is in the enhance-
ment of viral infectivity, which is independent of CD4
[8] or MHC class I [9] downregulation. Many studies
have suggested that the Nef incorporation into virions or
the association of virions with Nef is responsible for the
enhancement of viral infectivity mediated by Nef [10-15].
Welker et al. estimated that approximately 10 Nef mo-
lecules are incorporated into HIV-1 virions [13], much
fewer than the 275 molecules of another accessory pro-
tein, Vpr [16], which also has the capability to enhance
viral infectivity [17,18]. In many reports [15,19-25], it has
been suggested that Nef incorporated into virions could
exert its action in the early steps of infection, although the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Construction of short-lived Nef expression vector.
Schematic representations of Nef-WT and Nef-CP used in this study
(A). HEK293 cells were transfected with pNefmac239-WT or pNefmac239-CP.
After a 48 h cultivation, HEK293 cells transfected with pNefmac239-CP
were treated with 20 μM MG132 for 0 or 6 h. The cells were collected
and subjected to SDS-PAGE and western immunoblot analysis to
detect Nefmac239-WT and Nefmac239-CP using the anti-V5 antibody.
β-Actin was also detected using the anti-β-actin antibody, as described
in Materials and Methods (B). The relative band intensities of
Nefmac239-CP and β-actin were quantified using Fujifilm Image Gauge
software. The expression levels of Nefmac239-CP relative to those of
β-actin treated with and without MG132 were calculated using the
obtained intensities and compared (C).
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stantially unclear [26].
Although Nef is clearly one of the factors for the
pathogenesis induced by SIV in vivo [3], cell culture
studies of the role of Nef in the enhancement of the in-
fectivity of SIV [27] are not as intensive as those of HIV-1
described above. We, therefore, examined whether the
Nef incorporation into virions or the association of virions
with Nef is also important for the enhancement of the in-
fectivity of SIVmac239 as well as of HIV-1.
In this study, we generated short-lived Nef constructed
by fusing Nef to a proteasome-mediated protein degrad-
ation sequence, by which the balance between the synthe-
sis and degradation of Nef can be changed. Consequently,
the apparent expression level of Nef fused to the degra-
dation sequence becomes much lower than that of the
wild-type Nef. Accordingly, the frequency of the incorpor-
ation of the short-lived Nef into vitions or the association
of virions with the short-lived Nef would be lower than
that with the wild-type Nef. Interestingly, the infectivity of
SIVmac239 with the short-lived Nef was equivalent to that
with the wild-type Nef. On the other hand, the infectivity
of HIV-1NL4–3 with the short-lived Nef was significantly
lower than that with the wild-type Nef. These results sug-
gest that the mechanisms of the Nef-mediated enhance-
ment of infectivity are different between SIV and HIV-1.
Results
Construction of short-lived Nef expression vector
Some degradation signals conferring instability on pro-
teins have been found, which include the CL peptide [28]
and a murine ornithine decarboxylase (MODC) PEST re-
gion [29]. These signals induce a rapid protein degrad-
ation mediated by a proteasome, in which the CL peptide
requires ubiquitination prior to degradation, whereas the
PEST sequence requires no ubiqutination [14]. The CL
peptide and PEST sequence convert stable proteins into
unstable ones by attachment as fusion proteins [28,30-32],
whose apparent expression levels could be much lower
than those of the original proteins [30-33]. In this study,
we utilized a combination of two protein degradation se-
quences of the CL peptide and PEST sequence, namely,
the CP sequence, to generate short-lived Nef. We hypoth-
esized that the apparent expression level of short-lived
Nef is lower than that of wild-type Nef, which we evalu-
ated to determine whether the Nef incorporation into vi-
rions is associated with the enhancement of the infectivity
of SIVmac239.
To detect Nef by western immunoblot analysis under
the same conditions, the V5 epitope was appended at
the C-terminus of Nef to preserve the N-myristoylation
site of Nef, which is an essential posttranslational modi-
fication for Nef functions [6,7]. The CP sequence was
fused at the C-terminus of V5-tagged Nef (Figure 1A).Both wild-type (WT) Nef and CP-fused Nef were ex-
pressed under the control of the cytomegalovirus (CMV)
promoter. To verify the effect of the fused CP sequence
on Nef expression level, HEK293 cells were transfected
with plasmids encoding Nefmac239-WT or Nefmac239-CP,
which were from the SIVmac239 strain, and cultured for
72 h. The expression level of each Nef was evaluated by
immunoblot analysis using an anti-V5 antibody. As shown
in the two lanes on the left of Figure 1B, the apparent ex-
pression level of Nefmac239-CP was expectedly much lower
than that of Nefmac239-WT. Uniform sample loading was
confirmed by western immunoblot analysis of actin. As
expected, the mobility of Nefmac239-CP was slightly but
clearly lower than that of Nefmac239-WT with the fused
CP sequence. To confirm that the relatively low expres-
sion of level of Nefmac239-CP is due to the introduction
of the property of an extremely short life induced by
proteasome-mediated degradation, treatment with the
Figure 2 Difference in incorporation level in virions between
Nefmac239-WT and Nefmac239-CP. pBRmac239Δnef/luc was
cotransfected into HEK293 cells with either pNefmac239-WT,
pNefmac239-CP, or an empty vector. For virion preparation, the
supernatants were subjected to ultracentrifugation. Each viral pellet
was then subjected to SDS-PAGE and western immunoblot analysis
to detect Nef, Env, and p27, as described in Materials and Methods.
The mock sample was electrophoresed on a lane distant from two
lanes of the Nefmac239-WT and Nefmac239-CP.
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lysis was carried out, and Nefmac239-CP was then de-
tected by western immunoblot analysis. As shown in
the two lanes on the right of Figure 1B, the apparent ex-
pression level of Nefmac239-CP increased time-dependently
about 6-fold in the cells treated with MG132 for 6 h rela-
tive to the level in the untreated cells (Figure 1C). This re-
sult validates that the relatively low expression level of
Nefmac239-CP is due to its short-life property induced by
fusing Nef to the CP sequence.
Difference in incorporation level in virions between
Nefmac239-WT and Nefmac239-CP
Next, we examined the incorporation level of Nefmac239-CP
in the virions of SIVmac239. The nef-defective SIVmac239
provirus with the reporter gene was cotransfected into
HEK293 cells with or without the plasmid encoding
Nefmac239-WT or Nefmac239-CP. After a 72 h cultiva-
tion, the supernatants were collected by ultracentrifu-
gation and used in the viral preparation, as described in
Materials and Methods. The viruses were lysed and
subjected to immunoblot analysis to detect Nef. Uni-
form virion loading was confirmed by western immu-
noblot analysis of the SIV p27 core antigen. As shown
in the top panel of Figure 2, Nefmac239-WT was de-
tected in SIVmac239. However, under the same condi-
tions, Nefmac239-CP was not detected in SIVmac239, as in
the mock transfection control. This result clearly indi-
cates that the incorporation level of Nefmac239-WT is
higher than that of Nefmac239-CP.
HIV-1 Nef enhances the incorporation of the envelope
protein into virions [34]. Accordingly, we simultaneously
examined the incorporation level of the envelope protein
SIVmac239 virions. Western immunoblot analysis of the
viral envelope protein was performed. As shown in the
middle panel of Figure 2, the incorporation level of the en-
velope protein in SIVmac239 virions with Nefmac239-CP,
which was equivalent to that of the mock transfection
control, was clearly lower than that with Nefmac239-WT.
Altogether, the phenotype of SIVmac239 virions with
Nefmac239-CP was similar to that without Nefmac239.
Comparison of effects of Nef-WTs and Nef-CPs on
enhancement of SIVmac239 infectivity
The viral infectivity enhanced by Nefmac239-CP was
compared with that enhanced by Nef mac239-WT in
SIVmac239. To examine the effects of Nefmac239-WT
and Nefmac239-CP on SIV infectivity, HEK293 cells were
cotransfected with a nef-defective SIVmac239 provirus
with the luciferase reporter gene and the plasmid ex-
pressing Nefmac239-WT or Nefmac239-CP. Additionally,
plasmids expressing nonmyristoylated G2A mutants, i.e.,
Nefmac239-G2A and Nefmac239-CP-G2A, were also used as
nonfunctional Nef. The expression level of each Nef in thevirus-producing cells was examined by western immuno-
blot analysis of the obtained cell lysate. Indicator cells, i.e.,
MAGIC-5 cells, were inoculated with each supernatant
containing SIVmac239, and the luciferase activity of the
MAGIC-5 cells was measured after a 48 h cultivation, as
described in Materials and Methods. The MAGIC-5 cell
line is a HeLa cell derivative modified to express CD4 (the
primary receptor) and CCR5 (the coreceptor), respec-
tively, for the infection by SIVmac239 and CCR5-tropic
HIV-1. The infectivity of each virus was compensated for
by the amount of each SIV p27 antigen. The expression
level of each Nefmac239 derivative in each type of producer
cell is shown in the top panel of Figure 3A. Uniform
sample loading was confirmed by western immunoblot
analysis of actin. The expression levels of Nefmac239-CP
and Nefmac239-CP-G2A were much lower than those of
Nefmac239-WT and Nefmac239-G2A.
The comparison of the relative infectivities of SIVmac239
produced from HEK293 cells expressing all the Nefmac239
derivatives is shown in the bottom panel of Figure 3A.
The enhancement of the viral infectivity by Nefmac239-WT
Figure 3 (See legend on next page.)
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Figure 3 Comparison of effects of Nef-WTs and Nef-CPs on enhancement of viral infectivity. pBRmac239Δnef/luc was cotransfected
into HEK293 cells with either pNefmac239-WT, pNefmac239-CP, pNefmac239-G2A, pNefmac239-CP-G2A, or an empty vector (A). pBRmac239Δnef/luc
was cotransfected into HEK293 cells with either pNefJR-CSF-WT, pNefJR-CSF-CP, or an empty vector (B). pNL-CHΔenvΔnef/luc and psvJR-FLenv
were cotransfected into HEK293 cells with either pNefJR-CSF-WT, pNefJR-CSF-CP, or an empty vector (C). pNL-CHΔenvΔnef/luc and psvJR-FLenv
were cotransfected into HEK293 cells with either pNefmac239-WT, pNefmac239-CP, or an empty vector (D). After a 72 h cultivation, the cells were
collected and subjected to SDS-PAGE and western immunoblot analysis to detect Nef and β-actin, as described in Materials and Methods
(top panels). The supernatants were subjected to SIV p27 or HIV-1 p24 enzyme-linked immunosorbent assay (ELISA) and infectivity assay using
MAGIC-5 cells, as described in Materials and Methods (bottom panels). Each bar represents the mean standard deviation (n = 3).
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the viral infectivity by Nefmac239-G2A, a nonmyristoylated
and nonfunctional mutant, was not observed. Under this
condition, SIVmac239 with Nefmac239-WT was about 4-fold
more infectious than the virus without Nef. Unexpectedly,
the enhancement of the viral infectivity by Nefmac239-CP
was observed, although the apparent expression level of
Nefmac239-CP was much lower than that of Nefmac239-WT.
Interestingly, no significant difference in the enhancement
of viral infectivity between Nefmac239-WT and Nefmac239-
CP was observed. The enhancement by Nefmac239-CP was
abolished by the nonmyristoylated G2A mutation, as in
the case of the G2A mutation of Nefmac239-WT.
It was examined whether Nef from the HIV-1 strain can
enhance SIVmac239 infectivity similarly to Nefmac239-CP.
Nef from the JR-CSF strain of HIV-1, namely, NefJR-CSF,
was chosen in this study because the apparent expression
level of NefJR-CSF-WT is reported to be relatively higher
than those of other HIV-1 strains. The top panel of
Figure 3B shows the expressions of NefJR-CSF-WT and
NefJR-CSF-CP in the lysate of the virus-producing cells
determined by western immunoblot analysis. The ap-
parent expression level of NefJR-CSF-CP generated by
fusion of the Nef to the CP sequence was much lower
than that of NefJR-CSF-WT, and the mobility of the
weakly expressed NefJR-CSF-CP was lower than that of
NefJR-CSF-WT as in the case of Nefmac239-CP (Figure 1B).
Under this condition of the virus-producing cells, the
infectivity of each produced SIVmac239 with or without
NefJR-CSF-WT or NefJR-CSF-CP was examined. As shown
in the bottom panel of Figure 3B, significant enhancement
of the viral infectivity by NefJR-CSF-WT and NefJR-CSF-CP
in comparison with that in the case of a virus without
Nef was observed. Moreover, no significant difference
in the enhancement of viral infectivity between NefJR-CSF-
WT and NefJR-CSF-CP was observed, as in the case
of Nefmac239-WT and Nefmac239-CP. Altogether, these
results indicate that Nef-WTs and Nef-CPs show equi-
valent activities for the enhancement of SIVmac239 in-
fectivity in the case of Nef from not only SIVmac239 but
also HIV-1, even though the apparent expression le-
vels were markedly different between Nef-WTs and
Nef-CPs.Comparison of effects of Nef-WTs and Nef-CPs on
enhancement of HIV-1 infectivity
Many studies have suggested that the Nef incorporation
into virions or the association of virions with Nef is
responsible for the enhancement of the infectivity of
HIV-1 [10-13,15]. Accordingly, it has been expected that
the activity of Nef-CPs would be lower than that of Nef-
WTs in HIV-1. The effects of Nef-WTs and Nef-CPs
on HIV-1 infectivity were evaluated as follows. HEK293
cells were cotransfected with an env- and nef-defective
HIV-1NL4–3 provirus with the luciferase reporter gene
inserted into nef, a plasmid encoding a CCR5-tropic
JR-FL envelope protein, and a plasmid encoding either
NefJR-CSF-WT, NefJR-CSF-CP, Nefmac239-WT, or Nefmac239-
CP. To examine the infectivity, MAGIC-5 cells were in-
fected with the supernatants including CCR5-tropic
HIV-1NL4–3 and incubated for 48 h. Then, luciferase ac-
tivity as the indicator of infectivity was measured. The
infectivity of each virus was compensated for by the
amount of the p24 antigen of each virus. The top panel
of Figure 3C shows the expressions of NefJR-CSF-WT
and NefJR-CSF-CP in the virus-producing HEK293 cells
determined by western immunoblot analysis. Uniform
sample loading was confirmed by western immunoblot
analysis of actin. As expected, the expression level of
NefJR-CSF-CP was much lower than that of NefJR-CSF-
WT, whose expression profile was the same as that of
NefJR-CSF-WT or NefJR-CSF-CP expressed in SIVmac239-
producing cells (Figure 3B). Under this condition of the
virus-producing cells, the infectivity of HIV-1NL4–3 with
NefJR-CSF-WT was significantly much higher than that
of HIV-1NL4–3 without Nef. On the other hand, the in-
fectivity of HIV-1NL4–3 with NefJR-CSF-CP was significantly
lower than that of HIV-1NL4–3 with NefJR-CSF-WT, which
correlated with the expression levels of NefJR-CSF-WT and
NefJR-CSF-CP.
Next, it was examined whether Nefmac239-CP enhances
HIV-1NL4–3 infectivity. The top panel of Figure 3D shows
the expression profiles of Nefmac239-WT and Nefmac239-CP
in the lysate of the virus-producing cells by western im-
munoblot analysis. Uniform sample loading was con-
firmed by western immunoblot analysis of actin. The
expression level of Nefmac239-CP was found to be much
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pression profile as that of each Nefmac239 derivative
expressed in the SIVmac239-producing cells (Figure 3A).
Under this condition of the virus-producing cells, the
infectivity of HIV-1NL4–3 with Nefmac239-WT was sig-
nificantly much higher than that of HIV-1NL4–3 without
Nef. On the other hand, the infectivity of HIV-1NL4–3
with Nefmac239-CP was significantly lower than that of
HIV-1NL4–3 with Nefmac239-WT, which correlated with the
expression levels of Nefmac239-WTand Nefmac239-CP.
Taken together, the above results indicate that the ac-
tivity of enhancement of HIV-1 infectivity by Nef-CPs is
significantly lower than that by Nef-WTs, which were
from both SIVmac239 and HIV-1JR-CSF. The difference in
this activity between Nef-CPs and Nef-WTs was consid-
ered to be associated with the difference in apparent ex-
pression level between Nef-CPs and Nef-WTs. These
results for HIV-1 could support previous reports sug-
gesting that the Nef incorporation into virions or the
association of virions with Nef is responsible for the
enhancement of the infectivity of HIV-1 [10-13,15].
Therefore, the substantial enhancement of infectivity of
SIVmac239 by Nef-CP is again considered to be a unique
property.
Low expression level of Nefmac239 is not sufficient for the
enhancement of SIVmac239 infectivity
It was indicated that Nef-CPs could enhance the infect-
ivity of SIVmac239, whose apparent activity was equivalent
to those of Nef-WTs, although the apparent expression
levels of Nef-CPs were much lower than those of Nef-
WTs (Figures 3A and B). Typically, the activities of
Nef-CPs are lower than those of Nef-WTs for the en-
hancement of SIVmac239 infectivity, similarly to HIV-1
(Figures 3C and D). However, the profiles of the activities
of Nef-WTs and Nef-CPs for SIVmac239 were unexpectedly
but interestingly different from those for HIV-1. Here, we
hypothesized that even a very low expression level of Nef
is sufficient to enhance the infectivity of SIVmac239. To test
this hypothesis, a plasmid DNA encoding for Nefmac239-
WT was diluted to 1, 0.9, 0.5, 0.1, 0.05, and 0 μg, to which
mock empty plasmid DNA was added to a total 1 μg.
HEK293 cells were cotransfected with 1 μg of a plasmid
DNA mixture containing the indicated Nefmac239-WT-
encoding DNA and 1 μg of the nef-defective SIVmac239
provirus with the reporter gene. Moreover, HEK239
cells were cotransfected with 1 μg of plasmid DNA en-
coding for Nefmac239-CP and 1 μg of the nef-defective
SIVmac239 provirus with the reporter gene for compari-
son of the effect on infectivity between Nefmac239-WT
from DNA of various amounts and Nef mac239-CP from
1 μg of DNA.
At 72 h posttransfection and cultivation, the virus-
producing cells were lysed and subjected to westernimmunoblot analysis to detect Nefmac239-WT and Nef-
mac239-CP. At the same time, the supernatants were
evaluated for viral infectivity, as described above. As
shown in Figure 4A, a graded decrease in the expression
level of Nefmac239-WT was observed in a Nefmac239-WT
encoding DNA dose-dependent manner. A very low ex-
pression level of Nefmac239-CP from 1 μg of DNA was ob-
served, which was much lower than that of Nefmac239-WT
from 1 μg of DNA and was almost equivalent to that of
Nefmac239-WT from 0.05 μg of DNA. Under this condition
of each virus-producing cell type, the infectivity of each
SIVmac239 produced is shown in Figure 4B. A graded
decrease in infectivity of the virus was observed in a
transfected Nefmac239-WT encoding DNA dose-dependent
manner. The infectivity of SIVmac239 produced from the
cells transfected with 0.05 μg of DNA encoding Nefmac239-
WT was significantly lower than that transfected with
1 μg of DNA encoding Nefmac239-CP. On the other hand,
the infectivity of SIVmac239 produced by cells transfected
with 1 μg of DNA encoding Nefmac239-WT was almost
similar to that transfected with 1 μg of DNA encoding
Nefmac239-CP, whose result was the same as that shown in
Figure 3A. Taken together, these results indicate that such
a low expression level of Nefmac239-WT, which is similar
to that of Nefmac239-CP, is not sufficient to enhance the in-
fectivity of SIVmac239.
Discussion
Although the enhancement of viral infectivity by Nef is
clear, the molecular mechanism by which Nef enhances
the infectivity of HIV-1 and SIV remains unclear. In this
study, it was clearly indicated that there is a significant
difference between SIVmac239 and HIV-1NL4–3 in their re-
sponse to the infectivity enhancement by Nef-CP, sug-
gesting that the molecular mechanisms of Nef action
differ between SIVmac239 and HIV-1NL4–3.
It has been reported that HIV-1 Nef enhances the in-
corporation of envelope proteins into virions, which is
associated with the increase in HIV-1 infectivity [34].
Additionally, Nef incorporated into virions is suggested
to directly enhance virion infectivity in the early steps of
infection by HIV-1 [24,25]. In this study, it was observed
that the amount of envelope protein of SIVmac239 without
Nefmac239-WT was clearly lower than that with Nefmac239-
WT, suggesting that Nefmac239 can also enhance the in-
corporation of envelope proteins into SIVmac239 as in the
case of HIV-1 [34]. Thus, the amount of envelope protein
of SIVmac239 with Nefmac239-CP was clearly lower than that
with Nefmac239-WT, which was similar to that without
Nefmac239-WT (Figure 2). On the other hand, the infec-
tivity of SIVmac239 with Nefmac239-CP was interestingly
equivalent to that with Nefmac239-WT (Figure 3A). Ac-
cordingly, it is suggested that the enhancement of the
incorporation of the envelope protein into SIVmac239 by
Figure 4 Effect of low expression level of Nefmac239 on SIVmac239 infectivity. pBRmac239Δnef/luc was cotransfected into HEK293 cells with
1 μg of a mixture of pNefmac239-WT and an empty vector, at amounts of pNefmac239-WT in grams indicated. After a 72 h cultivation, the cells were
collected and subjected to SDS-PAGE and western immunoblot analysis to detect Nef and β-actin, as described in Materials and Methods (A).
The supernatants were subjected to SIV p27 ELISA and infectivity assay using MAGIC-5 cells as described in Materials and Methods (B). Each bar
represents the mean standard deviation (n = 3).
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viral infectivity by Nefmac239. Additionally, the direct ac-
tion of Nef incorporated to virions in the early step of
SIVmac239 infection is suggested to be not essential for
the enhancement of viral infectivity. Taken together, the
results suggest that the molecular mechanisms of the Nef-
mediated enhancement of viral infectivity are different be-
tween HIV-1 and SIVmac239. Furthermore, a mechanism
by which Nefmac239 can enhance SIVmac239 infectivity in-
side virus-producing cells, which is not associated withthe incorporation of envelope proteins into the virions,
may exist.
The N-myristoylation of Nef is essential for the major
functions of Nef [6]. The lack of effect of nonmyris-
toylated Nefmac239-CP-G2A on the enhancement of viral
infectivity (Figure 3A) indicates that the function of
Nefmac239-CP is also dependent on N-myristoylation
and may be dependent on membrane localization. Since
it was also confirmed that such a low expression level
of Nefmac239-WT from 0.05 μg of DNA, similar to that
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to enhance the infectivity of SIVmac239 (Figure 4), it is
hypothesized that a protein synthesis process for pro-
ducing a quorum of Nefmac239 molecules within a short
time in SIVmac239-producing cells is required for the
enhancement of viral infectivity even if the duration of
the presence of each molecule of Nefmac239 is extremely
short in the cell.
Lastly, we propose the following hypothesis: even
when the expression level of a protein such as Nef-CP is
extremely low, the protein may still be sufficiently func-
tional; this novel and unique hypothesis might be greatly
applicable in various fields such as biochemistry and cell
biology. Thus, a rapid turnover by not only rapid protein
degradation but also efficient production of a protein
through a strong promoter activity in transcription or ef-
ficient translation might be essential for the protein to
function sufficiently.
Conclusion
The findings suggest that the mechanisms of the en-
hancement of viral infectivity by Nef are different be-
tween HIV-1 and SIVmac239. Additionally, we propose
the following hypothesis: even when the expression




The infectious HIV-1NL4–3 expression vectors pNL-CH
[35] and psvJR-FLenv [36] were kindly gifted by Dr. Ron
Swanstrom of the UNC Center for AIDS Research, Uni-
versity of North Carolina at Chapel Hill, Chapel Hill,
NC. The infectious HIV-1 expression vector pYK-JRCSF
was obtained from the NIH AIDS reagent program.
Constructions of nef- and env-deficient and reporter-
gene-introduced SIVmac239 and HIV-1 expression vectors
Firefly-luciferase-encoding DNA was amplified by PCR
using a pGL4.14 [luc2/Hygro] vector (Promega, Madison,
Wi) and inserted into the nef-coding region of pBRmac239,
coding for SIVmac239 proviral DNA, as previously re-
ported [37]. The nef-deficient and luciferase-gene-
inserted SIVmac239 proviral DNA vector was named
pBRmac239Δnef/luc. To delete env of pNL-CH, the StuI
and BsaBI sites in env were digested by the corresponding
enzymes and the linear DNA obtained was subjected
to a ligation reaction, whose vector encoding the env-
deficient proviral DNA was named pNL-CHΔenv. Firefly-
luciferase-encoding DNA was amplified in PCR using a
pGL4.14 [luc2/Hygro] vector and inserted into the nef-
coding region using the Xho I site of pNL-CHΔenv, whose
vector with the luciferase reporter gene and without env
and nef was named pNL-CHΔenvΔnef/luc.Nef expression vectors
Nef-coding DNAs were amplified by PCR using the
corresponding proviral DNA templates (pBRmac239 for
Nefmac239 and pYK-JRCSF for NefJR-CSF) and subcloned
into pcDNA3.1D/V5-His TOPO according to the manu-
facturer’s instructions (Invitrogen, Carlsbad, CA). A Gly2-
to-Ala2 (G2A) mutation in nef was introduced using
site-directed mutagenesis. To introduce the short-life
property into the expressed Nef proteins, DNA encoding
a sequence of the CL peptide and the PEST, namely, the
CP sequence, was amplified from pGL4.78 [hRlucCP]
Hygro (Promega, Madison, Wi). The DNA was then linked
after the region of the V5 epitope tag encoding DNA using
the AgeI site of each Nef expression vector. All the con-
structed Nef expression vectors were named as follows:
pNefmac239-WT, pNefmac239-CP, pNefmac239-G2A, pNef-
mac239-CP-G2A, pNefJR-CSF-WT, and pNefJR-CSF-CP.Viral preparation
For the preparation of SIVmac239, pBRmac239Δnef/luc
was transiently cotransfected with either pNefmac239-WT,
pNefmac239-CP, pNefmac239-G2A, pNefmac239-CP-G2A,
pNefJR-CSF-WT, pNefJR-CSF-CP, or an empty vector into
HEK293 cells using Lipofectamine LTX reagent (Invitrogen,
Carlsbad, CA). For the preparation of CCR5 tropic
HIV-1NL4–3, pNL-CHΔenvΔnef/luc and psvJR-FLenv
were transiently cotransfected with either pNefmac239-
WT, pNefmac239-CP, pNefJR-CSF-WT, pNefJR-CSF-CP, or
an empty vector into HEK293 cells. At 72 h posttrans-
fection, the supernatants were collected and filtered
through a 0.45 μm filter and subjected to ELISA for
p27 or p24 antigen or viral infectivity assay. For virion
preparation, the supernatants were subjected to ultra-
centrifugation as previously described [38].Quantification of SIV p27 and HIV-1 p24 antigen in
supernatant
Each cell-free supernatant was filtered using a 0.45-μm-
pore-size filter and subjected to ELISA for SIV p27 or
HIV p24 (ZeptoMetrix Corporation, Buffalo, NY), ac-
cording to the manufacturer’s instructions.Measurement of viral infectivity
MAGIC-5 cells were inoculated with the supernatant as
previously described [39]. After a 72 h cultivation, the
cells were washed with PBS(−) and lysed with Cell Culture
Lysis Reagent (Promega, Madison, WI). The luminescence
of the firefly luciferase reporter was measured with a
luciferase assay system (Promega, Madison, Wi) using a
Wallac ARVO™ SX 1420 luminometer (Perkin-Elmer,
Waltman, MA).
Harada et al. Virology Journal  (2014) 11:222 Page 9 of 10Cell lysis and western immunoblot analysis
The cells were washed, lysed, and subjected to 5–20% poly-
acrylamide gradient sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) and western blot analysis.
The antibodies used in different immunoblottings were
as follows: anti-V5 antibody (Invitrogen, Carlsbad, CA),
anti-actin antibody (Oncogene, San Diego, CA), anti-gp130
SIV monoclonal antibody (Immuno Diagnostics, Inc.,
Woburn, MA), and anti-SIVmac239 monkey serum. Immu-
nocomplexes were detected using appropriate peroxidase-
conjugated secondary antibodies, followed by visualization
by chemiluminescence detection (NEN Life Science
Products, Boston, MA, USA) with LAS4000 (GE Health-
care, Buckingham, England). The intensities of the bands
were quantified with Fujifilm Image Gauge Software.
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